AbbVie, Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Janssen, Lilly, Merck, MSD, Novartis, Roche, Servier, and Takeda will all submit one or more products in the Best Pharmaceutical Agent and/or Best Biotechnological Product categories of the competition. Applications in those two categories are now closed.
With 14 multinational biopharmaceutical companies confirming their participation with a total of 30 products, the first Prix Galien Russia can already be called a success. Frédéric Boucheseiche, General Secretary of the Prix Galien Russia, said of the turnout, “this really exceeds our expectations, and we would like to thank all the participants for their support. We are more than happy about both the number and quality of the applications we are receiving, and the enthusiasm shown by pharmaceutical companies for the first national committee of the Prix Galien.”
The winners will be announced at the Gala dinner, to take place at the SwissÔtel convention center in Moscow on the 24th of October 2013.
For the special Prize for Research in Russia, Oncomax and Metamax—two companies backed by Maxwell Biotech Group, an RVC investment fund—have already confirmed their participation. So have Mitotech, a company backed by Rusnano and Generium.
Applications in this category will be accepted until the end of June. The Prize is open to academia, health care institutions, research centers, and companies that have been involved in biopharmaceutical research in Russia for at least three years. Applicants must demonstrate a substantial contribution to the diagnosis, prevention, or treatment of disease.
To apply or recommend candidates for the Special Prize, attend the Gala dinner, become a sponsor, or for further enquiries about Prix Galien Russia, please contact Crystelle Coury at email@example.com or log on www.prixgalienrussia.com